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Abstract
 
Thrombomodulin (TM) is a vascular endothelial cell (EC) receptor that is a cofactor for throm-
bin-mediated activation of the anticoagulant protein C. The extracellular NH
 
2
 
-terminal do-
main of TM has homology to C-type lectins that are involved in immune regulation. Using
transgenic mice that lack this structure (TM
 
LeD/LeD
 
), we show that the lectin-like domain of
TM interferes with polymorphonuclear leukocyte (PMN) adhesion to ECs by intercellular ad-
hesion molecule 1–dependent and –independent pathways through the suppression of extra-
cellular signal–regulated kinase (ERK)
 
1/2 
 
activation. TM
 
LeD/LeD 
 
mice have reduced survival after
endotoxin exposure, accumulate more PMNs in their lungs, and develop larger infarcts after
myocardial ischemia/reperfusion. The recombinant lectin-like domain of TM suppresses PMN
adhesion to ECs, diminishes cytokine-induced increase in nuclear factor 
 
 
 
B and activation of
ERK
 
1/2
 
, and rescues ECs from serum starvation, findings that may explain why plasma levels of
soluble TM are inversely correlated with cardiovascular disease. These data suggest that TM has
antiinflammatory properties in addition to its role in coagulation and fibrinolysis.
Key words: inﬂammation • coagulation • endotoxin • sepsis • protein C
 
Introduction
 
Thrombomodulin (TM)
 
*
 
 is a widely expressed glycopro-
tein receptor and cofactor for thrombin’s activity in a
physiologically important natural anticoagulant system.
Formation of the thrombin–TM complex limits throm-
bin’s procoagulant and cellular-activating functions and re-
sults in thrombin-mediated catalytic transformation of pro-
tein C (PC) into activated PC (APC), which in turn
down-regulates thrombin generation by degrading coagu-
lation factors Va and VIIIa. TM is also a cofactor for
thrombin-mediated activation of plasma procarboxypepti-
dase B, which is a fibrinolysis inhibitor. In humans, PC de-
ficiency is associated with a hypercoagulable state. Al-
though APC serves as an anticoagulant, it also has
antiinflammatory properties, a finding that may explain
why APC infusion reduces mortality in patients with sepsis
(1). As the critical cofactor for thrombin-mediated activa-
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Abbreviations used in this paper: 
 
AAR, area at risk; APC, activated pro-
tein C; BAL, bronchoalveolar lavage; EC, endothelial cell; EGF, epider-
mal growth factor; ERK, extracellular signal–regulated kinase; ES, embry-
onic stem; FPA, fibrinopeptide A; GST, glutathione 
 
S
 
 transferase; hpf,
high power fields; HUVEC, human umbilical vein EC; ICAM, intercellu-
lar adhesion molecule; LV, left ventricle; MAP, mitogen-activated protein;
MPO, myeloperoxidase; neo, neomycin phosphotransferase; PC, protein
C; PymT, middle T antigen of murine polyomavirus; TM, thrombomod-
ulin; UTR, untranslated region; VCAM, vascular cell adhesion molecule. 
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tion of PC, TM is an important bridge that links coagula-
tion and inflammation.
TM is composed of five structural domains. Extending
from a short cytoplasmic tail and transmembrane domain is
a serine/threonine–rich region to which a chondroitin sul-
fate moiety that optimizes anticoagulant function is at-
tached (2). Next is a domain that consists of six epidermal
growth factor (EGF)-like repeats, four of which are re-
sponsible for the protein’s anticoagulant and antifibrinolytic
functions (3, 4). The NH
 
2
 
-terminal domain has two mod-
ules. The first, adjacent to the EGF-like domain, is an
 
 
 
70–amino acid residue hydrophobic region. The second,
which is 
 
 
 
155–amino acid residues long, has homology to
C-type lectins (5), which in many proteins participate in
immune and inflammatory processes (6).
Mutational analyses of TM have been restricted to pa-
tients with venous or cardiovascular disease and therefore
its direct role in inflammation has not been evaluated. Al-
though single nucleotide polymorphisms of TM have
been weakly linked with heart disease, these amino acid
changes are not within the structures responsible for PC
activation (7). Soluble forms of TM derived from the ex-
tracellular domain of TM are found in plasma and urine
(8, 9). Clinical studies reveal an inverse correlation be-
tween plasma levels of soluble TM and coronary artery
disease and atherosclerosis (10). Although it has been pro-
posed that the EGF-like repeats of soluble TM promote
the generation of APC, which in turn inhibits atherogen-
esis, it is possible that other components of soluble TM
have independent vasculo-protective and antiinflamma-
tory functions.
To evaluate whether the NH
 
2
 
-terminal domain endows
TM with properties distinct from its established role in co-
agulation and fibrinolysis, we generated mice lacking this
structure. We report that the lectin-like domain of TM
provides the vascular endothelium with natural antiinflam-
matory properties by interfering with PMN adhesion. Mice
lacking the C-type lectin-like domain have an augmented
response to systemic endotoxemia, proinflammatory stimuli
in the lung, and myocardial ischemia/reperfusion (MI/R).
The lectin-like domain, either soluble or as an intact trans-
membrane glycoprotein, suppresses intracellular mitogen-
activated protein (MAP) kinase pathways, thereby dampen-
ing the inflammatory response. Soluble lectin-like domain
further protects vascular endothelial cells (ECs) from serum
deprivation–induced cell death. The ability of TM to pro-
vide natural antiinflammatory protection in concert with its
anticoagulant and EC protective properties provides new
insights for the development of novel therapies and the elu-
cidation of the etiology of a variety of inflammatory/prolif-
erative disorders.
 
Materials and Methods
 
Generation of Mice Lacking the NH
 
2
 
-terminal Lectin-like Domain of
TM via Homologous Recombination in Embryonic Stem (ES) Cells.
 
A 12-kb Kpn1 fragment of the murine 
 
TM
 
 gene containing the
 
coding region was subcloned as previously described (11). The
WT coding region was replaced with one that encodes TM lack-
ing the NH
 
2
 
-terminal domain using PCR-based mutagenesis.
Two PCRs were performed. In the first, primer TMs-240 (5
 
 
 
-
TTCTGTGGTGGCGCCTGCAGGCCACGCCCG) was paired
with antisense primer TMas287i (5
 
 
 
-ATTCTCCACGCTGCA-
TAGTGCGGAGAGCCCCAGGCTAGC), resulting in a 541-bp
fragment. In the second, sense primer TM.s1957i (5
 
 
 
-GGGC-
TCTCCGCACTATGCAGCGTGGAGAATGGTGGCTGT) and
TM.as2613EO (5
 
 
 
-TGGACTAGTTAATTAAGATCTTCCTC-
GAGGCGCGCCGTTCAGCTGAAATATTTTAGC) yielded
a 1,633-bp fragment. The amplicons were used as the target for
recombinant PCR with primers TM.s-240 and TM.as2613EO,
the latter primer adding Asc1, Xho1, BglII, Pac1, and Spe1 re-
striction sites. The recombined 2,206-bp amplicon extends from
a Nar1 site 230 bp upstream of the transcriptional start site,
through the coding region, and 643 bp into the 3
 
  
 
untranslated
region (UTR). The final translated protein product represents in-
tact TM, retaining the first 20 amino acid residues that encompass a
putative signal peptide and lacking the subsequent NH
 
2
 
-terminal
223 amino acid residues of the lectin-like domain (see Fig. 1 A).
A targeting vector to delete the NH
 
2
 
-terminal domain of TM
was constructed (see Fig. 1 A) as previously reported for deletion
of the cytoplasmic tail (11), except that 
 
loxP
 
 sites within the 3
 
 
 
-
UTR flanked a neomycin phosphotransferase (neo) gene. Not1-
linearized targeting vector DNA was introduced into R1 ES cells
by electroporation, and homologously recombined colonies were
identified by Southern blotting (see Fig. 1 B). The expected dele-
tion was confirmed by PCR of gDNA with primer pair TM.s99
(5
 
 
 
-GTCTAGGTTGTGATAGAGGCT) and TM.as1005 (5
 
 
 
-
GGCAGAGGCATCTGGGTTCATT), and DNA sequencing of
the 257-bp PCR product.
Targeted ES cells were aggregated and introduced into
pseudopregnant female Swiss white mice. Two chimeric male
offspring resulted in the germline transmission of the mutant 
 
TM
 
allele (TM
 
LeDneo/wt
 
). F1 and F2 offspring were intercrossed.
Genotyping was performed on the tail DNA by Southern blot-
ting and PCR (see Fig. 1 C). Chimeric males were backcrossed
with C57Bl/6 and 129sv/ev mouse pedigrees for comparative
purposes.
 
In Vivo Excision of loxP-flanked Neomycin Gene.
 
Mice with a
single allele replaced with the mutant TM
 
LeDneo 
 
(TM
 
LeDneo/wt
 
mice) were bred with mice homozygous for ubiquitous expres-
sion of Cre recombinase under the control of the phosphoglu-
cokinase promoter (12). In vivo excision of the 
 
loxP-
 
flanked neo
from the TM
 
LeDneo/wt 
 
mice was confirmed by PCR of gDNA and
RT-PCR on RNA from several tissues of offspring (see Fig. 1,
D–G). The oligonucleotide primer pair TM.s2520 (5
 
 
 
GGCTTTGGGTATTTAGTCAGA) and TM.as2700 (antisense
5
 
  
 
CATAAAACCCAGGCTCACCC) yielded an amplicon of
256 bp when excision was accomplished, whereas the product
was 174 bp in length from the WT allele. The resultant TM
 
LeD/wt
 
mice were intercrossed to generate mice with the TM mutation
in both alleles. WT siblings from these matings were used as con-
trols (TM
 
wt/wt 
 
mice).
 
Quantitation of TM, Cytokines, and Fibrinopeptide A (FPA).
 
Expression of cell surface TM was confirmed by indirect immu-
nofluorescence (13) using rabbit anti–rat TM antisera (provided
by R. Jackman, Brigham and Women’s Hospital, Boston, MA),
and cofactor activity was evaluated by the activation of PC with
thrombin (14). Tissue TM was quantified using a sandwich radio-
immunoassay similar to that previously reported (15). ELISA kits
(R&D Systems) were used to quantify plasma levels of TNF
 
 
 
, 
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IL-1
 
 
 
, IL-6, and IL-10. Plasma levels of murine FPA were mea-
sured as previously described (11).
 
Isolation and Growth of ECs.
 
ECs were isolated from murine
tumors induced to grow after intraperitoneal injection of retrovi-
rus carrying the middle T antigen of murine polyomavirus
(PymT; reference 16). Primary cultures of lymphatic ECs were
isolated from intraperitoneal lymphangiomas (17). Experiments
were performed with passages three to eight ECs, which were
cultured as previously described (13). 
 
 
 
95% of the cells stained
positive for TM and von Willebrand’s factor. Cell survival assays
of human umbilical vein ECs (HUVECs) were performed by
plating 50,000 cells/well in a 96-well plate in complete media.
After 24 h, cells were washed and incubated for 72 h in M199
with 0.05% serum and recombinant protein as indicated. Cell
survival was measured with the CellTiter 96 AQ
 
ueous 
 
One Solu-
tion Cell Proliferation Assay (Promega).
 
Flow Chamber Experiments.
 
PMNs were isolated from bone
marrow (18) and the purity was 
 
 
 
95% by Wright staining. Adhe-
sion of PMNs to ECs in a flow chamber was performed as previ-
ously described (19). In brief, ECs on collagen-coated glass cover-
slips were mounted in a parallel flow chamber and superfused
with PMN suspensions (2 
 
  
 
10
 
5 
 
cells/ml). Interactions of 2
 
 
 
7
 
 
 
-
bis-(2-carboxyethyl)-5-(and 6)-carboxyfluorescein–acetoxy-
methyl ester (BCECF-AM; Molecular Probes) –labeled PMNs
with ECs were observed with an inverted epifluorescence micro-
scope and images were analyzed with NIH Image1.6. Rolling
PMNs were counted on five overlays of video frames spanning 50
s of a 5-min experiment. Firm adhesion was determined on 15
high power fields (hpf; 0.9 mm
 
2
 
/hpf) after rinsing for 5 min.
Where noted, ECs were pretreated 4 h before experiments with
200 U/ml recombinant human TNF
 
  
 
(Biosource International).
 
Static Adhesion Assay.
 
ECs were grown to confluence in 24-
well dishes, washed twice with HBSS, and BCECF-AM–labeled
PMNs (50,000/well) were added in a final volume of 1 ml for 30
min. Monolayers were washed three times with HBSS and adher-
ent PMNs were counted.
 
In Vivo Activation of PC.
 
100 
 
 
 
g human PC (Enzyme Re-
search Labs) was injected intravenously into mice and 15 min
later citrated plasma was obtained. Plasma levels of activated hu-
man PC were quantified using a capture immunoassay with mAb
7D7B10 (provided by A. Ralston and C. Orthner, American
Red Cross, Washington, DC; references 20 and 21). Human PC
in murine plasma was measured with the Coamatic PC Assay Kit
(Chromogenix) using a standard curve with known quantities of
human PC in pooled murine plasma. Each result reflects duplicate
measures from at least five mice.
 
Flow Cytometry Analyses.
 
3 h after intraperitoneal injection of
PBS or 20 
 
 
 
g/g LPS (0111:B4; Sigma-Aldrich), mice were anes-
thetized and lung vasculature was perfused with PBS. Cell sus-
pensions from lungs (22) were incubated with biotinylated isolec-
tin B1 (
 
Bandeiraea simplicifolia
 
 I; Sigma-Aldrich) and 5 
 
 
 
g/ml
FITC-conjugated rat anti–mouse vascular cell adhesion molecule
(VCAM)-1 antibody (CD106) or PE-conjugated hamster anti–
mouse intercellular adhesion molecule (ICAM)-1 antibody
(CD54; BD Biosciences) at 37
 
 
 
C for 30 min. Suspensions with
CD106 or CD54 were additionally incubated with PE-streptavi-
din or FITC-streptavidin, respectively, followed by final washes
with PBS containing 10% FBS. Cell samples were analyzed by
flow cytometry using a FACScan™ (Becton Dickinson), gating
on isolectin positive ECs. Controls with appropriate irrelevant
antibodies excluded nonspecific labeling.
 
Endotoxin Studies.
 
LPS was injected intraperitoneally into
10–12-wk-old mice. For lethality studies, animals were moni-
 
tored until the recovery or cessation of breathing. For lung in-
flammation, 1 mg/ml endotoxin solution was nebulized into
mice housing for 10 min. Mice were killed 3 h later by urethane
overdose. Blood samples were drawn and the lungs were lavaged
five times through a tracheal catheter with 1 ml PBS/5% BSA at
37
 
 
 
C. Bronchoalveolar lavage (BAL) fluid was centrifuged at
4,000 
 
g 
 
for 5 min. The cell pellet was washed and resuspended in
PBS before cell counting and myeloperoxidase (MPO) activity
measurements (23). Lungs were dissected and prepared for histo-
logical analyses.
 
MI/R.
 
Myocardial ischemia was induced as previously de-
scribed (24). In brief, mice were ventilated and body temperature
was maintained at 36
 
 
 
C. The left anterior descending coronary
artery was ligated over PE-10 tubing. Ischemia of the left ventri-
cle (LV) was maintained for 30 min and then the tubing was re-
moved allowing reperfusion. 3 h later, heparinized saline was in-
fused into the abdominal aorta until no blood was collected from
a caval venotomy. The left anterior descending coronary artery
was reoccluded and Evans blue was injected into the aortic cathe-
ter to delineate the area at risk (AAR). The heart was excised, cut
into five slices, each 
 
 
 
1-mm thick, which were immersed in 2%
tetrazoliumchloride (25) for the determination of AAR, infarct
area, and LV size by planimetry of digitized images.
 
Generation of Recombinant Protein.
 
Recombinant murine TM,
representing the NH
 
2
 
-terminal 155 amino acids of the mature
protein (TM
 
lec155
 
) that was deleted in the TM
 
LeD/LeD 
 
mice (start-
ing with AKLQPT...; see Fig. 1) was generated by 
 
Pichia
 
 expres-
sion (Invitrogen). Additional purification was accomplished by a
series of chromatography steps, including elution of the culture
media from a phenyl-Sepharose column, desalting of positive
eluates on a G25 column, ion exchange and NaCl gradient elu-
tion from a Q-Sepharose column, and size fractionation with su-
perdex-75 in PBS with 0.01% Tween 80. Positive fractions, con-
firmed by SDS-PAGE and Western blotting with anti-TM
antisera, were pooled.
Recombinant TM
 
lec155 
 
was also generated as a glutathione 
 
S
 
transferase (GST) fusion protein (TM
 
lec155
 
-GST) by subcloning
the cDNA encoding the first 155 amino acids of TM into the
vector pGEX-4T-3 for expression in 
 
Eschericia coli
 
. Media con-
taining TM
 
lec155
 
-GST was incubated with glutathione-Sepharose,
washed, and the TM
 
lec155
 
-GST was eluted from the sepharose
beads with excess free glutathione.
 
Animal Care.
 
Animal experiments were approved by the In-
stitutional Animal Ethics Committee of the University of Leu-
ven, Leuven, Belgium.
 
Statistical Analyses.
 
Statistical analyses were conducted with
the computer programs StatView (Abacus Concepts Inc.) or In-
Stat 2.03 (GraphPad Software). Means are provided with SD
unless otherwise noted. P-values were determined using the un-
paired 
 
t
 
 test and groupwise comparisons by Wilcox-ranked sum
testing.
 
Results
 
Mice Lacking the NH
 
2
 
-terminal Domain of TM Are Via-
ble.
 
Germline transmission of the mutant 
 
TM
 
 allele (Fig.
1) lacking DNA encoding the NH
 
2
 
-terminal domain was
established. Crossbreeding of F1 TM
 
LeDneo/wt 
 
mice resulted
in 
 
 
 
250 offspring (26.1% TM
 
wt/wt
 
, 48.7% TM
 
LeDneo/wt
 
, and
25.2% TM
 
LeDneo/LeDneo
 
), indicating that intrauterine death
was not occurring. The neo gene in the 3
 
 
 
-UTR of the
mutant allele in TM
 
LeDneo/wt 
 
mice was excised in vivo. 
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The resultant TM
 
LeD/wt 
 
mice were intercrossed and the
genotypes of F2 progeny were also distributed in the ex-
pected pattern. Adult TMLeD/LeD and TMwt/wt mice had
similar lung TM antigen levels of 360   51 cpm/ g and
370    42 cpm/ g, respectively, whereas levels in the
lungs of TMLeDneo/LeDneo mice were  20% (74   18 cpm/
 g) of those in TMwt/wt and TMLeD/LeD mice. All F2 prog-
eny appeared healthy with no differences in weight, growth,
or fertility. Backcrossing onto 129sv/se and C57/Bl6
backgrounds resulted in similar phenotypes as reported
herein for the Swiss:129sv/se strain.
TMLeD/LeD Mice Have Increased Mortality and Heightened
Cytokine Response to Endotoxin. Baseline plasma levels of
TNF , IL-1 , IL-6, and IL-10 were undetectable in all
mice and circulating leukocyte counts were normal. 40
 g/g intraperitoneal LPS resulted in the death of  50% of
TMLeD/LeD mice within 26 h, whereas  10% of TMwt/wt
mice died during the same period (Fig. 2 A). After the ad-
dition of 20  g/g intraperitoneal LPS, TNF  and IL-1 
levels at 6 h were significantly higher in mice lacking the
NH2-terminal domain (P   0.05, n   18; Fig. 2 B). Pe-
ripheral leukocyte and PMN counts were not significantly
Figure 1. Generation of mice lacking the lectin-like do-
main of TM. (A) Strategy to introduce TM lacking the
NH2-terminal lectin-like domain into ES cells and mice
via homologous recombination. The WT allele for the TM
gene encodes a lectin-like domain (LLD), six EGF-like re-
peats (EGF), a serine-threonine rich region (STR), a trans-
membrane domain (TM), and a cytoplasmic tail (CT). The
amino acid sequence of the NH2-terminal domain that was
deleted is shown. (B) Southern blot of EcoR1-digested ES
cell gDNA from WT and homologously recombined cells
(lanes 1 and 2, respectively) detected with the 3 -external
Probe E. The targeted allele is represented with a 12-kb
fragment. (C) Southern blot of EcoR1/Xho1-digested tail
gDNA from TMwt/wt, TMLeDneo/wt, and TMLeDneo/LeDneo
mice (lanes 3, 4, and 5) detected with Probe E. WT and
targeted alleles are represented by 10.8- and 7.3-kb bands,
respectively. (D) Southern blot of EcoR1/Xho1-digested
tail gDNA from TMLeD/wt, TMwt/wt, and TMLeD/LeD mice
(lanes 6, 7, and 8) using Probe E. (E) Southern blot of
EcoR1/Xho1-digested tail gDNA from TMwt/wt, TMLeD/LeD,
and TMLeD/wt mice (lanes 9, 10, and 11) using a HindII/
Pme1 internal probe within the 5 -UTR. The WT and
targeted alleles are represented by 10.8- and 4.7-kb bands,
respectively. (F) PCR confirmation of Cre excision of neo-
mycin gene. Primers s2520 and as2700 were used with tail
gDNA from TMLeDneo/wt, TMLeD/wt, and TMLeD/LeD mice
(lanes 12, 13, and 14). The WT allele is seen as an  170-bp
amplicon, whereas Cre excision yields an  260-bp frag-
ment. Amplification did not occur across the intact neomy-
cin gene, explaining a single band in lane 12. (G) PCR
confirmation of the deletion of the lectin-like domain.
Primers s99 and as1005 resulted in an  930-bp amplicon
from the WT allele, and  260 bp from the targeted allele.
Gel shows PCR results using tail gDNA from TMwt/wt,
TMLeDneo/wt, TMLeDneo/LeDneo, and TMLeD/LeD mice (lanes
15, 16, 17, and 18).569 Conway et al.
different (P   0.1). The additional defect of lower TM an-
tigen levels in the TMLeDneo/LeDneo mice did not further af-
fect the cytokine response as compared with TMLeD/LeD
mice. Thus, the lack of the NH2-terminal domain of TM is
the sole cause of increased cytokine levels and reduced sur-
vival in response to systemic endotoxemia.
Leukocyte Extravasation into Lungs Is Increased in Mice Lack-
ing the NH2-terminal Lectin-like Domain of TM. Several in
vivo models were used to elucidate the function of the lec-
tin-like domain of TM in response to different inflamma-
tory stimuli. In histological sections of the lungs, before in-
tervention, the accumulation of leukocytes (95% PMNs,
5% monocytes) was notably increased in TMLeD/LeD and
TMLeDneo/LeDneo mice (Fig. 2, C and D) and distributed
throughout the interstitium in peribronchial locations, but
rarely in alveolar spaces. No differences were detected
when comparing TMLeD/LeD to TMLeDneo/LeDneo mice, indi-
cating that the mechanism is due to the lack of the lectin-
like domain rather than the diminished anticoagulant/anti-
fibrinolytic function.
As a trigger for leukocyte-induced lung injury, we ex-
posed mice to inhaled LPS. Baseline MPO activities in
BAL fluid were not significantly different between TMwt/wt
and TMLeD/LeD mice (87   17 and 92   23 absorbance
units, respectively; n   4), consistent with our observa-
tion that most PMNs were restricted to the lung intersti-
tium. After LPS inhalation, BAL MPO activity was 3.5-
fold higher in the TMLeD/LeD mice than in the TMwt/wt
mice (420   31 and 120   50 absorbance units, respec-
tively; P   0.005, n   8), whereas absolute PMN counts
were twofold higher. Ultrastructural examination of the
LPS-exposed lungs showed mild interstitial PMN accu-
mulation beyond the vessels in peribronchial sites and
within the alveoli. Therefore, the lack of the lectin-like
domain of TM results in enhanced PMN accumulation in
the lungs, an effect that is exacerbated by local exposure
to low levels of endotoxin.
TMLeD/LeD Mice Have Larger Infarcts after MI/R. PMN ex-
travasation and cytokine release are hallmarks of MI/R
injury (26). In a murine model, the LV area and AAR
(11.0   0.9 mm2 and 10.6   0.7 mm2, respectively; P  
0.1) were similar in TMLeD/LeD and TMwt/wt mice. However,
infarct sizes were significantly larger in TMLed/Led than in
TMwt/wt mice (Fig. 3, A and B), both as a function of LV
size and AAR (P   0.002). To correlate myocardial injury
with PMN accumulation, we injected labeled PMNs upon
reperfusion, counted adherent PMNs in sectioned hearts,
and compared results in corresponding regions of the hearts
from TMLed/Led and TMwt/wt mice (Fig. 3, C and D). An av-
erage of 22   5 PMNs were found in the AAR of TMwt/wt
mice. In the TMLed/Led mice, 2.5   0.7-fold more and 4.8  
0.9-fold more PMNs were found in the right and LV, re-
spectively, compared with TMwt/wt mice, indicating that
the extravasation of PMNs after MI/R is significantly en-
Figure 2. Response of TMLeD/LeD
mice to endotoxin. (A) TMLeD/LeD
mice and TMwt/wt sibling controls re-
ceived 40 ug/gm intraperitoneal LPS
and survival time was measured. For
each group, n   22. (B) 6 h after 20
ug/g intraperitoneal LPS, serum cy-
tokine levels and peripheral leuko-
cyte counts (WBC) were measured.
TNF   and IL-1   levels are signif-
icantly higher in TMLeD/LeD  and
TMLeDneo/LeDneo mice. For each group,
n   18. (C) Sections of lungs from
untreated TMwt/wt and (D) TMLeD/LeD
mice were immunostained with
MPO for monocytes/PMNs. Posi-
tively stained cells,  95% PMNs, are
readily detectable in the representa-
tive area from the TMLeD/LeD mice.570 Thrombomodulin’s Lectin Domain and Inflammation
hanced in the TMLeD/LeD mice (P   0.05, n   4 for each)
within and outside the ischemic regions.
Activation of PC by ECs Is Normal in TMLeD/LeD Mice.
The preceding results support the conclusion that the
NH2-terminal domain has a specific role in inflammation,
which in response to various proinflammatory stimuli, im-
pacts on several organ systems. To definitively exclude the
possibility that these findings reflect reduced functional ex-
pression of TM in TMLeD/LeD mice with consequent dimin-
ished activation of PC, independent methods were used to
evaluate APC generation.
We first confirmed that the capacity to activate PC was
intact in TMLeD/LeD mice by determining that the adminis-
tration of human PC did not result in significant differences
in plasma concentrations of APC in TMwt/wt and TMLeD/LeD
mice (P   0.5; Fig. 4 A). Although the addition of 20  g/g
intraperitoneal LPS 2 h before administering the PC
yielded higher levels of APC, there was no difference be-
tween the responses of TMwt/wt and TMLeD/LeD mice. We
then determined in vitro that the accumulation of TM
mRNA and cell surface thrombin-dependent activation of
PC by ECs derived from TMLeD/LeD and TMwt/wt mice
(TMLeD/LeD ECs and TMwt/wt ECs, respectively) were simi-
lar for both cultured lymphatic ECs and PymT-trans-
formed endothelioma cells (Fig. 4, B and C).
Although the data verify that PC activation is intact in
the TMLeD/LeD mice, we sought additional confirmation in
response to stresses. Predicting that a deficiency in APC
would be revealed by a hypercoagulable state, we exposed
mice to hypoxia (5.5% oxygen for 18 h; reference 11) to
provoke fibrin deposition. Baseline levels of lung tissue fi-
brin (21) were similar in TMwt/wt and TMLeD/LeD mice (25  
17 and 36   25  g/g, respectively; P   0.1, n   10/
group), as were plasma levels of FPA (3.2   2.1 and 4.6  
2.5 nM, respectively; P   0.1). Hypoxia did not affect ei-
ther of these measures. During hypoxia, one TMLeD/LeD
mouse and one TMwt/wt mouse died, whereas 7 of 18
TMLeDneo/LeDneo mice died with diffuse lung fibrin deposi-
tion, thus substantiating the model. To extend these obser-
vations, a second model was used to induce a hypercoagu-
lable state. 20  g/g intraperitoneal LPS induces fibrin
deposition in the lungs of TM-deficient mice with dimin-
ished PC cofactor activity (27). After this dose of LPS, fi-
brin deposits in sectioned lungs, brain, and kidney were
similar in the TMLeD/LeD and TMwt/wt mice and quantitative
levels of lung tissue fibrin were not increased from the
baseline in the TMwt/wt or TMLeD/LeD (unpublished data).
The results indicate that APC generation is not dimin-
ished in the TMLeD/LeD mice, supporting the conclusion
that the NH2-terminal lectin-like domain of TM plays a di-
rect role in interfering with the recruitment of inflamma-
tory cells.
Conversion of PMN Rolling to Firm Adhesion Is More Effi-
cient on TMLeD/LeD ECs. We evaluated the mechanisms re-
sponsible for excess accumulation of PMNs in the tissues of
TMLeD/LeD mice. Because PMNs and monocytes also syn-
thesize TM (28, 29), increased leukocyte efflux could re-
flect altered TM expression on inflammatory cells/endo-
thelium. To explore these possibilities, we first evaluated
the trafficking of PMNs from TMwt/wt and TMLeD/LeD mice
across fEND.5 cells, a PymT-transformed murine EC line
that expresses TM. At a laminar shear rate of 120s-1 in a
parallel plate flow chamber, the firm adhesion of PMNs
from TMwt/wt and TMLeD/LeD mice to unperturbed fEND.5
cells was 62   6 (SEM) and 63   8 (SEM) cells per 15 hpf,
respectively (n   5 experiments). After TNF  activation of
Figure 3. MI/R. (A) In repre-
sentative MI/R experiments, in-
farct size relative to AAR, delin-
eated by the dashed and solid
lines, respectively, is larger in
hearts from TMLeD/LeD  mice
(LeD) as compared with those
from TMwt/wt mice (wt). (B) In-
farct size, after MI/R, as a func-
tion of AAR is larger in hearts
from TMLeD/LeD mice. (C and D)
Labeled PMNs were injected
upon reperfusion during MI/R,
and PMN homing to each ven-
tricle was quantified. (C) Repre-
sentative sections with more
PMNs (arrows) homing to the
hearts of TMLeD/LeD mice. Arrow-
heads show the limit of the
AAR, delineated by thioflavin
fluorescence. (D) Fold increase,
relative to that observed with
TMwt/wt  mice, of adherent
PMNs to the LV and right ventri-
cle (RV) of hearts from TMwt/wt
and TMLeD/LeD mice. *, P   0.05.571 Conway et al.
the fEND.5 cells, the number of rolling TMwt/wt and
TMLeD/LeD PMNs and their rolling distances were similar,
whereas the speed of TMLeD/LeD PMNs was marginally re-
duced by  20% (similar results on TMwt/wt ECs; P   0.03).
With TNF  activation of fEND.5 cells, the adhesion of
TMwt/wt and TMLeD/LeD PMNs was similarly increased 1.6–
2-fold. Therefore, TM expression by TMLeD/LeD PMNs
does not appreciably contribute to the augmented PMN
extravasation observed in vivo in the TMLeD/LeD mice.
To examine the effect of endothelial TM on PMN traf-
ficking, we used PymT-transformed ECs from TMwt/wt and
TMLeD/LeD mice. Three different clones of ECs of each ge-
notype yielded similar results. Again, the source of the
PMNs had no significant effect on rolling/adhesion param-
eters. Under resting conditions, 11.1   6 (n   6) PMNs
rolled on TMwt/wt ECs, resulting in a permanent adhesion
of 36   9 PMNs (Fig. 5 A). Although the number of roll-
ing PMNs on resting TMLeD/LeD ECs was not significantly
different, the permanent adhesion of PMNs to the TMLeD/LeD
ECs was 7.8-fold greater than to the TMwt/wt ECs. Rolling
PMNs traveled 49   5  m on TMwt/wt ECs with an aver-
age speed of 0.7   0.06  m/sec (n   82) before adhering
or returning to the stream. In contrast, the distance traveled
by PMNs on TMLeD/LeD ECs was 30% less, and the PMN
rolling speed was 55% less than that seen with TMwt/wt ECs
(P   0.0001, n   286), indicating that the conversion of
PMNs from rolling to firm adhesion is more efficient on
TMLeD/LeD ECs.
Next, we studied the effects of the activation of ECs on
PMN rolling/adhesion. Stimulation of TMwt/wt ECs with
TNF  resulted in a 6.8-fold increase in firmly adhering
PMNs as compared with resting TMwt/wt ECs (Fig. 5 A).
Furthermore, the distance traveled by PMNs was reduced
by 56%, and their speed by 58% (P   0.0001, n   41), ev-
idence that TNF  enhances the conversion of PMN roll-
ing to firm adhesion. This effect was more pronounced
when TMLeD/LeD ECs were activated. PMN adhesion was
increased an additional 3.1-fold over that observed with ac-
tivated TMwt/wt ECs.
Similar increases in PMN adhesion to TMLeD/LeD ECs
were observed under static conditions (Fig. 5 A). Anti-TM
antisera, directed against regions within and outside the
NH2-terminal domain, increased PMN adhesion to TMwt/wt
ECs (P   0.005) to levels not different from those seen
with TMLeD/LeD ECs (P   0.05). However, the adhesion of
PMNs to TMLeD/LeD ECs was unaffected by anti-TM anti-
sera.
PMN Adhesion to TMLeD/LeD ECs Is ICAM-1–dependent
and –independent. To identify adhesion molecules mediat-
ing enhanced PMN extravasation in TMLeD/LeD mice, we
first determined by flow cytometry that suspensions of ECs
from lungs of TMLeD/LeD mice expressed more ICAM-1
(median fluorescence 20.2 vs. 4.8) and VCAM-1 (median
fluorescence 2.1 vs. 1.6) than ECs from lungs of TMwt/wt
mice (Fig. 6 A). Furthermore, the proportion of ECs from
the lungs of TMwt/wt and TMLeD/Led mice staining positive
for ICAM-1 was 68% and 98%, respectively, whereas for
VCAM-1 it was 38% and 51%, respectively. Western blot-
ting of heart lysates also showed greater expression of these
adhesion molecules in TMLeD/LeD mice before and after LPS
(Fig. 6 B). In view of the central role that ICAM-1 plays in
PMN–EC interactions, we characterized the extent of its
involvement in PMN adhesion to the TMLeD/LeD ECs in
dynamic studies (Fig. 5 B). ICAM-1 blocking did not affect
PMN rolling on either TMLeD/LeD or TMwt/wt ECs in the
presence or absence of TNF , nor did it alter adhesion to
resting TMwt/wt ECs. After TNF  activation of TMwt/wt
ECs, saturating amounts of anti–ICAM-1 antibodies (25
 g/ml) blocked 72   12% (n   5) of PMN adhesion. In
contrast, anti–ICAM-1 antibodies only reduced PMN ad-
hesion to resting TMLeD/LeD ECs by 42   4% (n   4) and
not to the level of adhesion seen with resting TMwt/wt ECs.
Figure 4. Activation of PC is nor-
mal in the absence of lectin domain
of TM. (A) Plasma levels of human
PC (hPC) and human APC (hAPC)
after infusion of hPC as described in
Materials and Methods. The results
reflect one of two representative ex-
periments with five mice in each
group. (B) Northern analysis of 20
 g total lymphatic EC RNA from
TMLeD/LeD  (LeD) or TMwt/wt  (wt)
mice, detected with a TM cDNA
probe. (C) ECs from TMwt/wt  or
TMLeD/LeD mice were cultured and
cell surface thrombin–dependent ac-
tivation of PC was measured. Re-
sults are representative of studies on
three clones.572 Thrombomodulin’s Lectin Domain and Inflammation
Anti–ICAM-1 antibodies also only partially blocked PMN
adhesion by 40   8% (n   7) to TNF -stimulated TMLeD/LeD
ECs. Indeed, suppression was not to the level of adhesion
seen with activated TMwt/wt ECs. Although these studies
suggest that ICAM-1–independent adhesion is partly re-
sponsible for the increased PMN adhesion to TMLeD/LeD
ECs, they also indicate that expression levels of ICAM-1
are significantly higher in TMLeD/LeD ECs than in TMwt/wt
ECs under the same conditions (P   0.03). Blocking both
P-selectin and ICAM-1 suppressed PMN adhesion by
 90% and rolling by 65% to TNF -treated ECs from ei-
ther TMLeD/LeD or TMwt/wt mice, which is evidence that the
predominant defect in TMLeD/LeD EC–PMN interactions
occurs after initial contact and rolling. Recent studies have
implicated VCAM-1 in mediating PMN emigration in
some models of inflammation (30). Consistent with these
observations, in preliminary studies maximal doses of anti–
VCAM-1 antibodies (25  g/ml) suppressed TNF-induced
PMN adhesion to TMLeD/LeD ECs by  40%. Overall, the
results indicate that receptors involved in PMN rolling are
intact in TMLeD/LeD ECs and both ICAM-1 and VCAM-1
enhance PMN adhesion to the TMLeD/LeD ECs, but addi-
tional ICAM-1– and VCAM-1–independent pathways are
also active in converting PMN rolling to firm adhesion.
Activation of Extracellular Signal–regulated Kinase (ERK)1/2 Is
Modulated by the NH2-terminal Domain of TM. The MAP
kinase intracellular signaling pathway is implicated in regu-
lating the expression of adhesion molecules (31). We ex-
amined the activation of ERK1/2 in heart lysates of mice
before and after LPS exposure. Total ERK1/2 levels re-
mained stable (Fig. 6 C). In mice treated with PBS, base-
line levels of phosphorylated ERK1/2 were similar between
genotypes. After LPS, heart lysates from TMwt/wt mice ex-
hibited little phosphorylation of ERK1/2. In contrast, a sig-
nificant increase in the activation of ERK1/2 was detected
in heart lysates of TMLeD/LeD mice. These data suggest that
the lectin-like domain of TM suppresses LPS-induced
phosphorylation of ERK1/2.
Soluble Lectin-like Domain of TM Suppresses ERK1/2 Activa-
tion, Interferes with PMN Adhesion to ECs, and Rescues ECs
from Serum-deprived Death. To further evaluate the role of
TM in PMN adhesion to ECs, we generated soluble re-
combinant forms of the molecule comprised of the C-type
lectin-like structure in Pichia pastoris (TMlec155) and a GST-
fusion protein (GST–TMlec155). In static assays (Fig. 7 A),
TMlec155 significantly reduced PMN adhesion to unstimu-
lated TMLeD/LeD ECs to levels observed with unstimulated
TMwt/wt ECs, and adhesion to fEND.5 cells to levels below
baseline. PMN adhesion to activated TMLeD/LeD ECs or ac-
tivated fEND.5 cells was suppressed by TMlec155 in a dose-
dependent manner. However, PMN adhesion to activated
fEND.5 cells could be suppressed to the level observed
with nonactivated fEND.5 cells, whereas TMlec155  sup-
pressed adhesion to activated TMLeD/LeD ECs only to the
level observed with activated TMwt/wt ECs (Figs. 5 A and 7
A). Although the extent of suppression varied in the cell
lines tested, soluble lectin-like domain uniformly interfered
with PMN adhesion to the ECs.
We predicted that soluble lectin-like domain of TM
would suppress PMN adhesion by altering the regulation of
MAP kinase pathways in ECs. Therefore, HUVECs were
exposed to 200 U/ml TNF  for 20 min. The accumula-
tion of pERK1/2 and NF- B were markedly suppressed,
although not totally abrogated, by the addition of GST-
TMlec155, whereas GST alone had no effect (Fig. 7 B). To-
tal ERK1/2 levels remained unchanged. TMlec155 similarly
Figure 5. PMN adhesion to
TMLeD/LeD and TMwt/wt ECs. (A)
Adhesion of PMNs from TMwt/wt
or TMLeD/LeD mice to ECs in flow
chamber (dynamic) or static adhe-
sion models was measured. Re-
sults reflect the mean of at least
three independent experiments
performed a minimum of three
times on three different clones.
PMN adhesion was significantly
greater to non-TNF–treated
TMLeD/LeD ECs than to TMwt/wt
ECs (P   0.005). Anti-TM anti-
sera increased PMN adhesion in
TMwt/wt  ECs (P    0.005), but
had no effect on PMN adhesion to
TMLeD/LeD ECs. (B) PMNs were
assessed for adhesion to TMwt/wt or
TMLeD/LeD ECs in a flow chamber
in the presence or absence of
TNF  and blocking anti–ICAM-1
and/or anti–P-selectin antibodies,
as described in Materials and
Methods and Results. PMN ad-
hesion to ECs is represented as a
fold increase over that observed
with quiescent TMwt/wt ECs.573 Conway et al.
interfered with TNF -induced up-regulation of pERK1/2
and NF- B expression by HUVECs, suggesting that the
lectin-like domain of TM suppresses PMN adhesion to
ECs via MAP kinase signaling.
Because EC death is a pathway of sustained tissue dam-
age, we evaluated whether TMlec155 was capable of rescu-
ing HUVECs from serum starvation–induced cell death.
After 3 d of serum deprivation,  95% of HUVECs died.
Serum starvation with the addition of TMlec155 at concen-
trations of 1, 10, and 20  g/ml rescued 2   0.6%, 18  
7%, and 34   14% of the cells (P   0.69, P   0.05, and
P   0.05, respectively, compared with serum-starved con-
trols), indicating that soluble TM may also have prosur-
vival properties.
Discussion
Transgenic mice lacking the NH2-terminal domain of
TM (TMLeD/LeD mice) have normal TM antigen levels and
retain the capacity to generate APC. Compared with
TMwt/wt mice, TMLeD/LeD mice exhibit reduced survival in
response to endotoxin, have elevated serum cytokine lev-
els, and respond to local proinflammatory stimuli with aug-
mented PMN adhesion, extravasation, and subsequent tis-
sue damage. Even without exposure to inflammatory
stimuli, TMLeD/LeD mice accumulate more PMNs in their
lung parenchyma, possibly increasing their risk of tissue
damage. These results suggest that the NH2-terminal lec-
tin-like domain of TM has direct antiinflammatory proper-
ties, thereby extending its function to a system beyond co-
agulation and fibrinolysis.
Although it has long been recognized that the coagula-
tion system modulates inflammation, only recently has the
impact of this contribution been appreciated, and some of
the molecular links been established. The PC pathway is
particularly relevant (32), a fact highlighted by the demon-
stration that APC infusion reduces mortality in patients
with sepsis (1).
As the critical cofactor for PC activation, TM is an obli-
gate participant in the regulation of inflammation. Cyto-
kines and PMN-derived elastase suppress endothelial TM
functional and antigenic expression (33, 34), resulting in
decreased APC generation, which contributes to the
thrombotic and inflammatory components of coronary
atheroma (35). Independent of its role in PC activation, we
hypothesized that the NH2-terminal domain of TM might
be important in immune defense because of its homology
to C-type lectins.
Figure 6. Up-regulation of adhe-
sion molecules in TMLeD/LeD mice.
(A) Flow cytometric detection of
adhesion molecules. After gating on
isolectin positive ECs (20,000
events) of lung suspensions from
TMwt/wt  (red) and TMLeD/LeD  mice
(green), surface expression of
VCAM-1 and ICAM-1 was de-
tected. In this representative experi-
ment, more adhesion molecule ex-
pression is observed for TMLeD/LeD
cells. (B) Western immunoblot of
heart lysates from TMwt/wt (wt) or
TMLeD/LeD  (LeD) mice 3 h after
treatment with intraperitoneal PBS
( ) or 20 ug/g LPS ( ). In each
lane, 200  g total protein was
added. (C) Western immunoblots of
heart lysates of mice treated as in B.
Total ERK1/2  and tubulin show
equal loading of protein. Generation
of activated ERK1/2 (pERK1/2) is in-
creased in LPS-exposed hearts of
TMLeD/LeD mice.574 Thrombomodulin’s Lectin Domain and Inflammation
The family of C-type lectins has several members includ-
ing, for example, the selectins (36) and rat AA4 antigen
(37). Through interactions with carbohydrate recognition
domains, lectins participate in innate immune functions
such as opsonization, complement activation, and leuko-
cyte homing (6, 38). Electron microscopic analysis suggests
that the lectin-like domain of TM is globular and well-situ-
ated for interactions with other proteins or cells (39), as it is
located furthest from the membrane surface. The remark-
able similarity between AA4 and TM in terms of their
structural organization, cellular distribution, and colocaliza-
tion of their genes to the same chromosomal region (40)
suggests a common ancestry and possibly common func-
tions. However, AA4 promotes leukocyte adhesion (40),
whereas TM interferes with PMN adhesion. It will be in-
teresting to explore the possibility that TM and AA4 play
opposing roles in inflammation and do so via common in-
teracting proteins/intracellular signaling pathways.
To elucidate the mechanism(s) by which the tissues of
TMLed/Led mice accumulate more PMNs, we studied leu-
kocyte trafficking and established that even though TM is
expressed by PMNs, monocytes, and ECs (28, 29), the
critical determinant regulating PMN adhesion is restricted
to the NH2-terminal domain of endothelial TM. En-
hanced PMN adhesion to resting TMLeD/LeD ECs suggests
that these cells are in a basal proadhesive state, consistent
with the findings of excess PMNs in the lungs and in-
creased recruitment of PMNs to nonischemic regions of
the hearts of TMLeD/LeD mice. In spite of enhanced firm ad-
hesion to TMLeD/LeD ECs, flow chamber studies indicate
that PMN rolling is not affected by lack of the lectin-like
domain. Thus, it is possible that the lectin-like domain
competes for selectin-mediated outside-in signaling, an
event that initiates downstream firm adhesion (41). Conse-
quently, lack of this domain would result in sustained sig-
nals and increased expression of proadhesive molecules.
ICAM-1, which is higher in the lungs, hearts, and ECs of
TMLed/Led mice, clearly contributes to augmented PMN
adhesion in TMLed/Led mice. Interestingly, VCAM-1 ex-
pression was also augmented in the lungs and hearts of
TMLeD/LeD mice. Although VCAM-1 has not traditionally
been viewed as a major player in PMN trafficking, recent
reports show that  4 1 (VLA-4) integrin and VCAM-1
may contribute to PMN migration in some tissues in re-
sponse to specific inflammatory stimuli (30, 42), notably
including MI/R. As with anti–ICAM-1 antibodies, anti–
VCAM-1 antibodies only partially interfered with PMN
adhesion to cytokine-stimulated TMLeD/LeD  ECs. These
data indicate that VCAM-1 and ICAM-1 mediate, in part,
the proinflammatory phenotype of the TMLeD/LeD mice,
but also suggest that other adhesion molecules, recruited
via signals modulated by the lectin-like domain of TM,
contribute to this phenomenon. Additional studies are
necessary to explore the relative contribution of these and
other proadhesive molecules in specific vascular beds under
different inflammatory conditions.
Figure 7. Effects of soluble lectin-
like domain of TM on PMN adhe-
sion, NF- B, and MAP kinase acti-
vation. (A) In a static adhesion
model, TMlec155  significantly de-
creased PMN adhesion to TMLeD/LeD
ECs and fEND.5 cells. (B) Regula-
tion of ERK activation by soluble
lectin-like domain of TM. HUVECs
were exposed to TNF  (1), TNF 
plus  GST (2), TNF   plus GST-
TMlec155 (3), or TNF  plus TMlec155
(4) for 20 min. Western immuno-
blots of cell lysates detected TNF -
induced up-regulation of pERK1/2
and NF- B, which were suppressed
by the addition of GST-TMlec155 or
TMlec155. No change in total ERK1/2
was detected. In the absence of
TNF , there was no detectable
pERK1/2 or NF- B (not depicted).575 Conway et al.
Recent in vitro data indicate that APC mediates intracel-
lular signals that down-regulate NF- B, ICAM-1, VCAM-1,
and E-selectin gene expression (43). The lectin-like domain
of TM may function via similar intracellular pathways. In-
deed, the lectin-like domain of TM when constitutively
expressed on the cell surface, facilitates intracellular signal-
ing that suppresses PMN adhesion. This interaction may be
reversed in response to ischemic or inflammatory stimuli if
this domain is cleaved by elastase, or expression of TM is
down-regulated (14, 44). Lack of the lectin-like domain of
TM in the heart and lungs of TMLeD/LeD mice results in the
activation of MAP kinase ERK1/2, a signaling pathway that
leads to the up-regulation of proinflammatory molecules
(31). It is unlikely that the cytoplasmic domain of TM is di-
rectly involved in transmitting these signals, because mice
lacking this domain do not have an altered cytokine re-
sponse (unpublished data; reference 11). Alternatively, sig-
naling may occur from the NH2-terminal domain of TM
to other associated cell surface or extracellular soluble pro-
teins, or via its transmembrane domain. Similar examples of
cross talk between integrins and other membrane receptors
have been documented (45).
Because the tertiary structure of TM is unknown, we
cannot exclude the possibility that the NH2-terminal do-
main masks a proadhesive domain on TM. A likely candi-
date region would be the first two EGF-like repeats, these
structures being classically involved in protein–protein in-
teractions. These EGF-like repeats could provide a recep-
tor site for activated PMNs that is unmasked during inflam-
mation by allosteric changes in the NH2-terminal domain
or by its cleavage by proteases released from PMNs. Thus,
our finding that exogenous soluble TM decreases activation
of ERK1/2, NF- B, and PMN adhesion could be explained
in part by steric interference with the proadhesive effect of
the EGF-like repeats.
Extravasation of activated PMNs during MI/R results in
tissue injury that may be attenuated by preventing the ex-
pression of cell adhesion molecules such as P-selectin, E-selec-
tin, and ICAM-1 (46). Two polymorphisms of TM, one
within the sixth EGF-like repeat (A455V; reference 47)
and one within the lectin-like domain (Ala25Thr; refer-
ence 48), are associated with increased risk of coronary ar-
tery disease/myocardial infarction. The increase in infarct
size in the TMLed/Led mice after MI/R supports a direct car-
dioprotective role for the NH2-terminal domain, at least in
part by interfering with PMN extravasation and cytokine
generation. It is intriguing to consider that soluble TM, ei-
ther the anticoagulant EGF-containing fractions or those
fractions that contain the NH2-terminal domain, might be
directly protective, thereby explaining the Atherosclerosis
Risk in Communities Study results in which plasma TM
levels were inversely correlated with incident coronary
heart disease (10). This hypothesis is also supported by a re-
port that soluble human urinary TM, composed of the en-
tire extramembranous portion of TM, prevented hepatic
ischemia/reperfusion injury in dogs (49).
Our observation that the lectin-like domain of TM at-
tenuates MAP kinase activation is also interesting in light of
clinical data demonstrating an inverse correlation between
tumor cell proliferation and TM expression (50). MAP ki-
nase signaling may enhance cellular proliferation by in-
creasing cyclin D1. In tumor models, lack of the NH2-ter-
minal domain of TM enhances cell growth (51), an effect
that may reflect augmented MAP kinase activation. The
clinical significance of these findings is highlighted by stud-
ies demonstrating that soluble TM has thrombin-indepen-
dent antitumor effects (52).
Our studies show that the NH2-terminal lectin-like do-
main of TM modulates inflammation by attenuating MAP
kinase activation and interfering with PMN–EC interac-
tions. We also demonstrate that soluble lectin-like domain
enhances cell survival. TM is therefore an example of a
highly regulated, multidomain molecule that provides mo-
lecular links between several biological systems. Conse-
quently, we predict that mutations in different functional
domains of TM produce distinct disease states. Searches
have identified TM mutations that are associated with in-
creased thrombotic risk (53, 54), and the Ala25Thr muta-
tion/polymorphism in the lectin-like domain is linked with
a higher risk of myocardial infarction (48). Computer mod-
eling indicates that Ala25 is located on an exposed surface
of the lectin-like structure. Thus, a mutation at Ala25
could alter the overall hydrophobicity and/or its interac-
tion with other proteins, resulting in a change in function.
This finding underlines the importance of considering TM
mutations when searching for the etiology of inflamma-
tory/proliferative disorders.
Lastly, the therapeutic potential of these findings cannot
be overlooked. Although APC has been shown to provide
protection from sepsis, this treatment is not uniformly ef-
fective nor is it without a risk of bleeding (1). Studies are
underway to determine whether nonanticoagulant forms of
soluble TM have therapeutic benefit.
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